{"id":405289,"date":"2020-12-23T15:27:19","date_gmt":"2020-12-23T20:27:19","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=405289"},"modified":"2020-12-23T15:27:19","modified_gmt":"2020-12-23T20:27:19","slug":"acasti-pharma-unaware-of-any-material-change","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/acasti-pharma-unaware-of-any-material-change\/","title":{"rendered":"Acasti Pharma Unaware of Any Material Change"},"content":{"rendered":"
\n

LAVAL, Qu\u00e9bec, Dec. 23, 2020 (GLOBE NEWSWIRE) — At the request of IIROC, Acasti Pharma Inc. (\u201cAcasti or the \u201cCompany\u201d) (NASDAQ: ACST \u2013 TSX-V: ACST) wishes to confirm that the Company\u2019s management and Board of Directors are unaware of any material change in the Company\u2019s operations that would account for the recent increase in market activity.<\/p>\n

\n About Acasti <\/strong>\n <\/p>\n

Acasti is a biopharmaceutical innovator that has historically focused on the research, development and commercialization of prescription drugs using OM3 fatty acids delivered both as free fatty acids and bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have extensive clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being developed for patients with severe HTG.<\/p>\n

\n F<\/strong>
\n o<\/strong>
\n rw<\/strong>
\n a<\/strong>
\n rd<\/strong>
\n L<\/strong>
\n oo<\/strong>
\n king<\/strong>
\n S<\/strong>
\n t<\/strong>
\n a<\/strong>
\n tem<\/strong>
\n e<\/strong>
\n n<\/strong>
\n ts<\/strong>\n <\/p>\n

\n Statements in this press release that are not statements of historical or current fact constitute \u201cforward-looking information\u201d within the meaning of Canadian securities laws and \u201cforward-looking statements\u201d within the meaning of U.S. federal securities laws (collectively, \u201cforward-looking statements\u201d). Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Acasti to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms \u201cbelieves,\u201d \u201cbelief,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201canticipates,\u201d \u201cpotential,\u201d \u201cshould,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cplans,\u201d \u201ccontinue\u201d, \u201ctargeted\u201d or other similar expressions to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. <\/em>\n <\/p>\n

\n The forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement, the \u201cSpecial Note Regarding Forward-Looking Statements\u201d section contained in Acasti\u2019s latest annual report on Form 10-K and quarterly report on Form 10-Q<\/em>
\n ,<\/em>
\n which are available on EDGAR at <\/em>
\n
\n www.sec.gov\/edgar\/shtml<\/em>
\n <\/a>
\n , on SEDAR at www.sedar.com and on the investor section of Acasti\u2019s website at www.acastipharma.com. All forward-looking statements in this press release are made as of the date of this press release. Acasti does not undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking <\/em>
\n statements contained herein are also subject generally to assumptions and risks and uncertainties that are described from time to time in Acasti\u2019s public securities filings with the Securities and Exchange Commission and the Canadian securities commissions, including <\/em>
\n Acasti\u2019s latest annual report on Form 10-K<\/em>
\n and quarterly report on Form 10-Q under the caption \u201cRisk Factors\u201d. <\/em>\n <\/p>\n

\n Neither NASDAQ, the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/em>\n <\/p>\n

\n A<\/strong>
\n c<\/strong>
\n a<\/strong>
\n s<\/strong>
\n t<\/strong>
\n i<\/strong>
\n C<\/strong>
\n on<\/strong>
\n t<\/strong>
\n a<\/strong>
\n c<\/strong>
\n t:
<\/strong>Jan D\u2019Alvise
Chief Executive Officer
Tel: 450-686-4555
Email: i<\/a>n<\/a>fo@<\/a>a<\/a>castip<\/a>h<\/a>a<\/a>r<\/a>ma.<\/a>c<\/a>o<\/a>m
<\/a>www.<\/a>a<\/a>castip<\/a>h<\/a>a<\/a>r<\/a>ma.c<\/a>o<\/a>m<\/a><\/p>\n

\n Investor <\/strong>
\n C<\/strong>
\n on<\/strong>
\n t<\/strong>
\n a<\/strong>
\n c<\/strong>
\n t:
<\/strong>Crescendo Communications, LLC
Tel: 212-671-1020
Email: ACST@crescendo-ir.com<\/a>\u00a0<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

LAVAL, Qu\u00e9bec, Dec. 23, 2020 (GLOBE NEWSWIRE) — At the request of IIROC, Acasti Pharma Inc. (\u201cAcasti or the \u201cCompany\u201d) (NASDAQ: ACST \u2013 TSX-V: ACST) wishes to confirm that the Company\u2019s management and Board of Directors are unaware of any material change in the Company\u2019s operations that would account for the recent increase in market activity. About Acasti Acasti is a biopharmaceutical innovator that has historically focused on the research, development and commercialization of prescription drugs using OM3 fatty acids delivered both as free fatty acids and bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have extensive clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being … <\/p>\n

Continue reading “Acasti Pharma Unaware of Any Material Change”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-405289","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAcasti Pharma Unaware of Any Material Change - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/acasti-pharma-unaware-of-any-material-change\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Acasti Pharma Unaware of Any Material Change - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LAVAL, Qu\u00e9bec, Dec. 23, 2020 (GLOBE NEWSWIRE) — At the request of IIROC, Acasti Pharma Inc. (\u201cAcasti or the \u201cCompany\u201d) (NASDAQ: ACST \u2013 TSX-V: ACST) wishes to confirm that the Company\u2019s management and Board of Directors are unaware of any material change in the Company\u2019s operations that would account for the recent increase in market activity. About Acasti Acasti is a biopharmaceutical innovator that has historically focused on the research, development and commercialization of prescription drugs using OM3 fatty acids delivered both as free fatty acids and bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have extensive clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being … Continue reading "Acasti Pharma Unaware of Any Material Change"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/acasti-pharma-unaware-of-any-material-change\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-23T20:27:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNzIzOCMzODk1MjQ1IzIwOTM5MDY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acasti-pharma-unaware-of-any-material-change\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acasti-pharma-unaware-of-any-material-change\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Acasti Pharma Unaware of Any Material Change\",\"datePublished\":\"2020-12-23T20:27:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acasti-pharma-unaware-of-any-material-change\\\/\"},\"wordCount\":557,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acasti-pharma-unaware-of-any-material-change\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExNzIzOCMzODk1MjQ1IzIwOTM5MDY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acasti-pharma-unaware-of-any-material-change\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acasti-pharma-unaware-of-any-material-change\\\/\",\"name\":\"Acasti Pharma Unaware of Any Material Change - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acasti-pharma-unaware-of-any-material-change\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acasti-pharma-unaware-of-any-material-change\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExNzIzOCMzODk1MjQ1IzIwOTM5MDY=\",\"datePublished\":\"2020-12-23T20:27:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acasti-pharma-unaware-of-any-material-change\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acasti-pharma-unaware-of-any-material-change\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acasti-pharma-unaware-of-any-material-change\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExNzIzOCMzODk1MjQ1IzIwOTM5MDY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExNzIzOCMzODk1MjQ1IzIwOTM5MDY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acasti-pharma-unaware-of-any-material-change\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Acasti Pharma Unaware of Any Material Change\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Acasti Pharma Unaware of Any Material Change - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/acasti-pharma-unaware-of-any-material-change\/","og_locale":"en_US","og_type":"article","og_title":"Acasti Pharma Unaware of Any Material Change - Market Newsdesk","og_description":"LAVAL, Qu\u00e9bec, Dec. 23, 2020 (GLOBE NEWSWIRE) — At the request of IIROC, Acasti Pharma Inc. (\u201cAcasti or the \u201cCompany\u201d) (NASDAQ: ACST \u2013 TSX-V: ACST) wishes to confirm that the Company\u2019s management and Board of Directors are unaware of any material change in the Company\u2019s operations that would account for the recent increase in market activity. About Acasti Acasti is a biopharmaceutical innovator that has historically focused on the research, development and commercialization of prescription drugs using OM3 fatty acids delivered both as free fatty acids and bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have extensive clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being … Continue reading \"Acasti Pharma Unaware of Any Material Change\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/acasti-pharma-unaware-of-any-material-change\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-23T20:27:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNzIzOCMzODk1MjQ1IzIwOTM5MDY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acasti-pharma-unaware-of-any-material-change\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acasti-pharma-unaware-of-any-material-change\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Acasti Pharma Unaware of Any Material Change","datePublished":"2020-12-23T20:27:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acasti-pharma-unaware-of-any-material-change\/"},"wordCount":557,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acasti-pharma-unaware-of-any-material-change\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNzIzOCMzODk1MjQ1IzIwOTM5MDY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acasti-pharma-unaware-of-any-material-change\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/acasti-pharma-unaware-of-any-material-change\/","name":"Acasti Pharma Unaware of Any Material Change - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acasti-pharma-unaware-of-any-material-change\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acasti-pharma-unaware-of-any-material-change\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNzIzOCMzODk1MjQ1IzIwOTM5MDY=","datePublished":"2020-12-23T20:27:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acasti-pharma-unaware-of-any-material-change\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/acasti-pharma-unaware-of-any-material-change\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acasti-pharma-unaware-of-any-material-change\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNzIzOCMzODk1MjQ1IzIwOTM5MDY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNzIzOCMzODk1MjQ1IzIwOTM5MDY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acasti-pharma-unaware-of-any-material-change\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Acasti Pharma Unaware of Any Material Change"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/405289","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=405289"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/405289\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=405289"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=405289"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=405289"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}